An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder

被引:0
|
作者
Castry, Mathieu [1 ]
Tin, Yjuliana [2 ]
Feder, Noah M. [3 ]
Lewis, Nikki [4 ]
Chatterjee, Avik [4 ,5 ]
Rudorf, Maria [4 ]
Samet, Jeffrey H. [4 ,5 ]
Beers, Donna [4 ]
Medley, Bethany [6 ]
Gilbert, Louisa [6 ]
Linas, Benjamin P. [1 ,5 ]
Barocas, Joshua A. [2 ]
机构
[1] Boston Med Ctr, Sect Infect Dis, Boston, MA USA
[2] Univ Colorado, Div Gen Internal Med & Infect Dis, Sch Med, 12631 E 17th Ave,Mailstop B180, Aurora, CO 80045 USA
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] Boston Med Ctr, Sect Gen Internal Med, Boston, MA USA
[5] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[6] Columbia Univ, Sch Social Work, Social Intervent Grp, New York, NY USA
来源
JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT | 2024年 / 167卷
基金
美国国家卫生研究院;
关键词
Mobile health units; Opioid use disorder; Harm reduction; Medications for opioid use disorder; Economic evaluation; OVERDOSE; MASSACHUSETTS; BUPRENORPHINE; PROGRAM; IMPACT; STATES;
D O I
10.1016/j.josat.2024.209517
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background & objective: Mobile substance use treatment units are effective approaches to increase treatment access and reduce barriers to opioid use disorder (OUD) care. However, little is known about the economic costs of maintaining and operating these units. This study aimed to estimate the economic costs of starting and maintaining mobile units providing harm reduction, overdose education and naloxone distribution (OEND), and medication for opioid use disorder (MOUD). Methods: As part of the HEALing Communities Study, four communities in Massachusetts (Bourne/Sandwich, Brockton, Gloucester, Salem) implemented mobile units offering OEND and MOUD (buprenorphine and naltrexone only); each selected different services tailored to their community. All provided MOUD linkage via telehealth, but only one offered in-person MOUD prescribing on the unit. We retrospectively collected detailed resource utilization data from invoices to estimate the direct economic costs from August 2020 through June 2022. Cost components were categorized into start-up and operating costs. We calculated total economic cost over the study period and the average monthly operating cost. Results: Implementing a mobile unit offering OEND and MOUD required a one-time median start-up cost of $59,762 (range: $52,062-$113,671), with 80 % of those costs attributed to the vehicle purchase. The median monthly operating cost was $14,464. The largest cost category for all mobile units was personnel costs. The monthly ongoing costs varied by community settings and services: approximately $5000 for two urban communities offering OEND and MOUD linkage via telehealth (Gloucester, Salem), $28,000 for a rural community (Bourne/Sandwich), and $23,000 for an urban community also providing in-person MOUD prescribing on the unit (Brockton). Conclusion: The economic costs of mobile substance use treatment and harm reduction units are substantial but vary by community settings and services offered. Our results provide valuable community-level economic data to stakeholders and policymakers considering establishing and/or expanding mobile units with OEND and MOUD services. Further exploration of cost-effectiveness and efficiency should be considered across different settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Dynamics of prescribing and accessing medications for opioid use disorder: a community-based systems analysis
    Herman, Tianna
    Hasgul, Zeynep
    Lim, Tse Yang
    Jalali, Mohammad S.
    Stringfellow, Erin J.
    ADDICTION RESEARCH & THEORY, 2024,
  • [22] Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review
    Bailey, Amelia
    Dacunha, Alyssa
    Napoleon, Siena C.
    Kang, Augustine W.
    Kemo, Madeleine
    Martin, Rosemarie A.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 164
  • [23] Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder
    Enns, Benjamin
    Krebs, Emanuel
    Whitehurst, David G. T.
    Jutras-Aswad, Didier
    Le Foll, Bernard
    Socias, M. Eugenia
    Nosyk, Bohdan
    DRUG AND ALCOHOL DEPENDENCE, 2023, 247
  • [24] Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits and healthcare cost compare to late initiation
    Sun, Tianyu
    Aroke, Hilary
    Kogut, Stephen
    Katenka, Natallia
    Bratberg, Jeffrey
    Buchanan, Ashley
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2022, 48 (02) : 217 - 225
  • [25] Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
    Fatema Z. Ahmed
    Barbara Andraka-Christou
    M.H. Clark
    Rachel Totaram
    Danielle N. Atkins
    Brandon del Pozo
    Health & Justice, 10
  • [26] Barriers to medications for opioid use disorder in the court system: provider availability, provider "trustworthiness," and cost
    Ahmed, Fatema Z.
    Andraka-Christou, Barbara
    Clark, M. H.
    Totaram, Rachel
    Atkins, Danielle N.
    del Pozo, Brandon
    HEALTH & JUSTICE, 2022, 10 (01)
  • [27] Barriers and Facilitators to Harm Reduction for Opioid Use Disorder: A Qualitative Study of People With Lived Experience
    Westafer, Lauren M.
    Beck, Samantha A.
    Simon, Caty
    Potee, Benjamin
    Soares, William E.
    Schoenfeld, Elizabeth M.
    ANNALS OF EMERGENCY MEDICINE, 2024, 83 (04) : 340 - 350
  • [28] Attitudes of Black American Christian church leaders toward Opioid Use Disorder, overdoses, and harm reduction: a qualitative study
    Dankwah, Akosua B.
    Siegrist Jr, Richard B.
    Wilson, Ira B.
    McKenzie, Michelle
    Rich, Josiah D.
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [29] A Harm Reduction Framework for Integrated Treatment of Co-Occurring Opioid Use Disorder and Trauma-Related Disorders
    Israel, Benjamin S.
    Belcher, Annabelle M.
    Ford, Julian D.
    JOURNAL OF DUAL DIAGNOSIS, 2024, 20 (01) : 52 - 85
  • [30] Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review
    Noa Krawczyk
    Adetayo Fawole
    Jenny Yang
    Babak Tofighi
    Addiction Science & Clinical Practice, 16